Macrophages can alternate between two states: an inflammatory state for fighting infection and a non-inflammatory state for ...
Clinical Trials Arena on MSN
Agomab’s ALK5 inhibitor to advance to Phase IIb in Crohn’s disease
Ontunisertib could become the first FDA-approved anti-fibrotic suitable for Crohn’s disease patients with symptomatic ...
Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...
14h
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment -- -- Pharmacokinetic results confirm gut-restricted profile of ontunisertib in FSCD patients -- -- ...
UChicago Medicine has opened the first clinic of its kind in Chicago, and one of only a few nationwide, focused on preconception and pregnancy care for patients with Crohn’s disease and ulcerative ...
Anti-interleukins and JAK inhibitors are linked to a reduced serious infection risk among patients with ulcerative colitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback